CBD

Given the fast and furious mobilization of the global healthcare community to understand the nature of the coronavirus, how to treat it, and, eventually, how to prevent it, the sheer volume of research on COVID-19 is not at all surprising. What is, perhaps, surprising, especially given how recently it’s been since the COVID-19 breakout, is that there are so many research publications on the potential for cannabis to be used to treat the virus. On the other hand, perhaps the abundance of research on cannabis for COVID-19 is not so surprising. After all, it is a virus that causes an immune response, which may escalate into a virulent inflammatory reaction. And an enormous body of research on cannabis—and cannabidiol (CBD) in particular—has shown cannabis to induce strong anti-viral and anti-inflammatory effects. It is still early days, so no clinical studies establishing the efficacy of cannabis for COVID-19 have yet been conducted, but studies have established several clear mechanisms of action for using cannabis to treat COVID-19.

This article reviews several studies on CBD dosages and what they mean for consumers and the industry.

As markets mature, manufacturing terpene blends have become a new art form and a differentiating factor for potential therapeutic applications. Here, we dive deeper into the insights of terpene formulation considerations.

In this blog installment, we take a deep dive into research on how cannabis affects neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

A cannabis-based treatment was shown to be effective for cognitive disfunctions.

Our sister publication, Nutritional Outlook, recently published an article covering the year in CBD and looking ahead to what’s on the horizon in 2024.

A recent study examined adult use of four cannabinoids within the past year.

A recent study tested the safety and efficacy of cannabidiol in relieving emergency dental pain.

Researchers analyzed several bone samples from a hospital crypt and detected two cannabinoids.

Japan is amending a piece of hemp legislation which will help expand rules regarding hemp but would restrict cannabis regulation.

This blog installment looks at the use of cannabis for pets. Topics covered include the history of cannabis use in veterinary medicine, current laws on cannabis for pets, market size and segment, reported experiences from both pet owners and veterinarians, and pet toxicology.

Our sister publication, DVM 360, recently covered a patent issued to ElleVet Sciences for their CBD + CBDA hemp extract forumulation.

Our sister publication, Dermatology Times, discussed how cannabis-based personal care products suddenly seem ubiquitous all over the market, where CBD is a featured ingredient in everything from moisturizers and lotions to makeup.

Whether someone is struggling with acute or chronic pain, cannabis can be a powerful tool as an alternative or adjunct treatment.

Our sister publication, LCGC, recently covered updates on the new mobile HPLC system for cannabis analysis selected by the Food and Drug Administration.

Read coverage from our sister publication, Nutritional Outlook, on “The Hemp Access and Consumer Safety Act,” which was previously proposed in 2021.

Our sister publication, dvm360, recently published an article discussing a study that was funded by the Morris Animal Foundation and was conducted by veterinary research team at the University of Saskatchewan located in Saskatoon, Saskatchewan, Canada.

ProjectCBD provided a detailed summary of some of the recent research on cannabis for treating irritable bowel disease (IBD).

A Brazilian university has detected cannabidiol (CBD) in a native plant called Trema micrantha blume.

Listen to Part II of this Noid Factoid from Nick Jikomes, PhD, the Director of Science & Innovation at Leafly.

The webinar "Cannabis and Dementia: Unlocking the Potential" was held on June 14, 2023, and featured four panelists’ experiences treating dementia symptoms with cannabis.

The Kansas City Royals have partnered with Pure Spectrum CBD, becoming the second MLB team to form such a partnership.

The cannabidiol (CBD) market reached a saturation level in recent years with products popping up around every corner—from the local gas station to the neighborhood market and more. How can consumers know which of those products are safe and reliably labeled? It is an unfortunate fact that there are bad products on the market, some that have no CBD at all despite label claims. Despite these bad actors, many companies are striving to do better and even set higher standards for the industry. For instance, Vantage Hemp Co. has made it their mission to go beyond current state requirements and produce pharmaceutical-grade CBD. Here, Deepank Utkhede, Chief Operating Officer at Vantage Hemp Co., discusses his role with the company and their goals to elevate this market to create a safe place for consumers and manufacturers.

Our sister publication, Oncology Nursing News recently published an interview with Karen Hande, PhD, DNP, ANP-BC, CNE, FAANP, ANEF, where she discusses increased patient interest in cannabinoids and how oncology nurses can steer pain management conversations to keep patients informed.

This article provides insights into the opportunities involving the genetic modification of cannabis.